Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Patented DehydraTECH™ Platform Increases CBD Tissue Absorption by 1,937%
DehydraTECH™ drug delivery platform achieved a 319% higher CBD blood concentration level at 60 minutes than the generic coconut oil formulation The technology can be used on the nicotine market, the pharmaceutical market, and the cannabinoid market No other company in the world has a patent for improved delivery of all non-psychoactive cannabinoids Partnership with one of the world’s largest tobacco companies with up to $12 million in Lexaria funding for clinical investigations and product development Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has launched a revolutionary technology that accelerates intestinal absorption of bioactive substances administered without the need for…
